Remission in Subjects With Crohn's Disease, 1 Year Phase

Completed · Phase 3 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of adalimumab when administered to participants with Crohn's disease up to 56 weeks.

Key facts

Study ID
NCT00055497
Run by
Abbott
People needed
276
Starts
2002-08-01
Expected to finish
2008-12-01
Last updated by the study team
2011-04-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.